Biomarkers Predicting Treatment Outcome in Depression: What is Clinically Significant?
- 18 January 2012
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 13 (2) , 233-240
Abstract
Aim: To extend to biomarker studies the consensus clinical significance criterion of a three-point difference in Hamilton Rating Scale for Depression. Materials & methods: We simulated datasets modeled on large clinical trials. Results: In a typical clinical trial comparing active treatment and placebo, a difference of three Hamilton Rating Scale for Depression (HRSD) points at the end of treatment corresponds to 6.3% of variance in outcome explained. To achieve a similar explanatory power, genotypes with minor allele frequencies of 5, 10, 20, 30 and 50% need to attain a per allele difference of 4.7, 3.6, 2.8, 2.4 and 2.2 HRSD points, respectively. A normally distributed continuous biomarker will need an effect size of 1.5 HRSD points per standard deviation. A number needed to assess of three suggests that with this effect size, a biomarker will significantly improve the prediction of outcome in one out of every three patients assessed. Conclusion: This report provides guidance on assessing clinical signi...Keywords
Funding Information
- Innovative Medicine Initiative Joint Undertaking (115008)
- EU and the European Federation of Pharmaceutical Industries and Associations
- EU’s Seventh Framework Program (FP7/2007-2013)
- National Institute of Mental Health (MH086026)
This publication has 30 references indexed in Scilit:
- Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptylineJournal of Affective Disorders, 2011
- Personalized Medicine for Depression: Can We Match Patients With Treatments?American Journal of Psychiatry, 2010
- A Genomewide Association Study of Citalopram Response in Major Depressive DisorderBiological Psychiatry, 2010
- Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease riskHuman Molecular Genetics, 2009
- When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D StudyNeuropsychopharmacology, 2009
- Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug AdministrationPLOS Medicine, 2008
- Measuring depression: comparison and integration of three scales in the GENDEP studyPsychological Medicine, 2007
- The Montgomery Äsberg and the Hamilton ratings of depression: A comparison of measuresEuropean Neuropsychopharmacology, 2006
- The cost of dichotomising continuous variablesBMJ, 2006
- Power considerations when a continuous outcome variable is dichotomizedJournal of Biopharmaceutical Statistics, 1998